ERBB2 and breast carcinoma: Triple-negative breast cancer is more likely to recur as compared with other breast cancer subtypes, with five-year specific survival rates of 85% for stage 3 triple-negative cancer, as compared with survival rates ranging from 94-99% for hormone receptor-positive and ERBB2-positive cancers (24).